Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.16360 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Mouse Model of Enthesis-Specific NF-κB Activation.
J Orthop Res
January 2025
Department of Biomedical Engineering, Columbia University, New York, New York, USA.
Enthesitis, or inflammation specific to sites in the body where tendon inserts into bone, can arise in isolated joints from overuse or in multiple joints as a complication of an autoimmune condition such as psoriatic arthritis or spondyloarthritis. However, the pathogenesis of enthesitis is not well understood, so treatment strategies are limited. A clinically relevant animal model of enthesitis would allow investigators to determine mechanisms driving the disease and evaluate novel therapies.
View Article and Find Full Text PDFExploring the Link Between Psoriasis and Adipose Tissue: One Amplifies the Other.
Int J Mol Sci
December 2024
Unit of Dermatology, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
Psoriasis and obesity, while distinct, are inter-related inflammatory conditions. Adipose tissue (AT)-derived mediators could be pathogenically active in triggering and/or amplifying psoriatic skin inflammation and, vice versa, skin inflammation could drive increased adiposity that triggers the development of several chronic conditions. Gaining insight into their intricate relationship could be essential for effective management and treatment.
View Article and Find Full Text PDFClinical features, treatment, and outcomes of nivolumab induced psoriasis.
Invest New Drugs
December 2024
Department of Pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, Changsha, Hunan, 410013, China.
Psoriasis is an uncommon immune-mediated adverse event linked to nivolumab, and its clinical characteristics remain inadequately defined. This study aims to investigate the clinical features and patterns of nivolumab-induced psoriasis, providing insights for the identification and management of this condition. Case reports and case series of nivolumab related psoriasis were gathered by searching Chinese and English databases for retrospective analysis until June 30, 2024.
View Article and Find Full Text PDFChallenging case of and in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies.
Med Mycol Case Rep
December 2024
Dermatology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", 00133, Rome, Italy.
Psoriasis is a multifactorial immune-mediated disorder linked to the interleukin (IL)-17 signalling pathway. We present an unusual case of and caused by that developed after starting the IL-17A/F inhibitor bimekizumab. Our case underlines how psoriatic patients, treated with IL-17 inhibitors, should be screened for cutaneous fungal infections before and during treatment, in order to exclude a concomitant infection or the risk of its exacerbation.
View Article and Find Full Text PDFClinical Characteristics and Management of Drug-Induced Lupus Caused by Tumor Necrosis Factor Inhibitors: A Comprehensive Review.
Cureus
October 2024
Internal Medicine, Bahçeşehir University, Istanbul, TUR.
Article Synopsis
- TNF inhibitor (TNFi) therapy is used for autoimmune diseases like ankylosing spondylitis and rheumatoid arthritis but can lead to drug-induced lupus (DIL), though this is rare.
- DIL from TNFi usually presents with mild symptoms, and most patients show anti-double-stranded DNA positivity without severe complications, meaning major organ involvement is uncommon.
- Management strategies differ; some patients can remain on TNFi therapy, while others need different treatments, indicating a need for more research to enhance treatment protocols and patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!